Provided by Tiger Trade Technology Pte. Ltd.

Neurosense Therapeutics Ltd

3.82
-0.2500-6.14%
Volume:12.89K
Turnover:49.56K
Market Cap:7.21M
PE:-0.44
High:4.07
Open:3.95
Low:3.79
Close:4.07
52wk High:26.64
52wk Low:3.79
Shares:1.89M
Float Shares:1.29M
Volume Ratio:0.44
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.7319
EPS(LYR):-8.7319
ROE:-2174.98%
ROA:-247.30%
PB:-4.62
PE(LYR):-0.44

Loading ...

Neurosense Therapeutics Receives Nasdaq Listing Compliance Notice

MT Newswires Live
·
Oct 03

NeuroSense Faces NASDAQ Delisting Risk After Missing $35 Million Market Value Rule

Reuters
·
Oct 03

Neurosense Provides Update on NASDAQ Listing Compliance

THOMSON REUTERS
·
Oct 03

NASDAQ Trade Halt Volatility Trading Pause at 09:46 Am

Reuters
·
Sep 30

NeuroSense CFO Eisenberg Joins ROTH Healthcare Opportunities Conference Investor Meetings

Reuters
·
Sep 29

NeuroSense target adjusted to $52 from $8 at H.C. Wainwright

TIPRANKS
·
Sep 28

Neurosense Therapeutics Ltd : H.c. Wainwright Adjusts Target Price to $52 from $8 to Reflect 1-for-20 Reverse Stock Split

THOMSON REUTERS
·
Sep 28

Press Release: NeuroSense Provides Business Update and Progress for the First Half of 2026

Dow Jones
·
Sep 26

NASDAQ Trade Halt Continues Reason not Available at 06:55 Am

Reuters
·
Sep 14

Neurosense Therapeutics Ltd trading halted, news pending

TIPRANKS
·
Sep 12

NASDAQ Trade Halt Halt News Pending at 07:50 Pm

Reuters
·
Sep 12

NeuroSense Therapeutics to Present at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 10

Neurosense Therapeutics Ltd: to Effect Reverse Share Split of Co’s Ordinary Shares at Ratio of 1-for-20

THOMSON REUTERS
·
Sep 10

NeuroSense Therapeutics Effects 1-for-20 Reverse Stock Split on Sept. 14, 2026

Reuters
·
Sep 10

NeuroSense Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Sep 03

Neurosense Therapeutics Ltd. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $8

THOMSON REUTERS
·
Sep 03

NeuroSense announces redesigned development plan for PrimeC

TIPRANKS
·
Aug 31

NeuroSense Targets Faster, Lower-Cost ALS Approval Path for PrimeC Under Revamped Development Plan

Reuters
·
Aug 31

NeuroSense Plans Head-to-Head PrimeC Trial Versus Mitsubishi Tanabe’s Edaravone in ALS

Reuters
·
Aug 31

Neurosense Unveils Accelerated, Capital-Efficient Strategy to Advance Primec Toward Potential Approval in ALS

THOMSON REUTERS
·
Aug 31